This phase I/II study is evaluating how safe, tolerable and effective a new targeted therapy (AZD9574) is alone, or in combination with chemotherapy (temozolomide) in people with advanced solid cancers.
This trial is treating patients with ovarian, fallopian tube or primary peritoneal cancer, breast cancer, castration-resistant prostate cancer, pancreatic cancer, and IDH1/2-mutant glioma.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has not spread to other parts of the body.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)
This study has two Modules. Module 1 has two parts. In Module 1 Part 1, participants with advanced or relapsed ovarian, breast, pancreatic or prostate cancer who are suitable for a Poly ADP-Ribose Polymerase (PARPi) will receive AZD9574 (orally) as monotherapy in escalating cohorts. In Module 1 Part 2, participants with breast cancer who are PARPi naive will receive AZD9574 (orally) at a dose determined in Part 1. At this stage, Module 2 only has one part but a second part may be added in future. In Module 2 Part 1, participants with IDH 1/2-mutant glioma who are PARPi naive will receive AZD9574 (orally) and temozolomide (orally) at escalating doses.
Recruiting Hospitals Read More